title: Survival in cervix cancer patients treated with radiotherapy followed by radical surgery.
abstract: OBJECTIVE
  To determine the incidence and predictive value of residual disease in the hysterectomy specimens of cervical cancer patients treated with primary radiotherapy, with or without chemotherapy, followed by surgery and to determine whether pathologically confirmed residual disease is a surrogate marker of outcome.
  
  
  METHODS
  The medical records of patients treated for stage IB/II carcinoma of the cervix in a single institution between 1985 and 2000 were retrospectively analysed into two different groups, depending on whether they had received radiotherapy or concurrent chemo-radiotherapy. Six to 8 weeks after irradiation, all patients underwent radical or extrafascial hysterectomy and pelvic and para-aortic lymphadenectomy.
  
  
  RESULTS
  A total of 403 patients were included in the study (360 in the radiotherapy only group and 43 in the chemo-radiotherapy group). One hundred and seventy-eight patients had residual disease on hysterectomy specimens in the radiotherapy group. Considering only the stages IB2 and II, 126 (52%) and 16 (37%) patients had residual disease on hysterectomy specimens in the radiotherapy group and in the chemo-radiotherapy group, respectively (P=0.08). Residual disease was associated with pelvic and para-aortic nodal metastases. The 5-year local control and overall survival rates were 88 and 86%, respectively, in the patients with complete pathologic response and 73 and 62%, respectively, in the patients with residual disease (P<0.001). In multivariate analysis, FIGO stage, residual disease, and pathologic nodal involvement were independent predictive factors of both local recurrence and overall survival.
  
  
  CONCLUSIONS
  Pathologically confirmed residual disease on hysterectomy specimen is an independent and strong predictive factor of both local recurrence and overall survival.
authors.affiliation: Department of Surgical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. rrouzier@mdanderson.org
authors.forename: R
authors.initials: R
authors.lastname: Rouzier
authors.forename: P
authors.initials: P
authors.lastname: Morice
authors.forename: R
authors.initials: R
authors.lastname: De Crevoisier
authors.forename: C
authors.initials: C
authors.lastname: Pomel
authors.forename: A
authors.initials: A
authors.lastname: Rey
authors.forename: K
authors.initials: K
authors.lastname: Bonnet
authors.forename: A
authors.initials: A
authors.lastname: Recoules-Arche
authors.forename: P
authors.initials: P
authors.lastname: Duvillard
authors.forename: C
authors.initials: C
authors.lastname: Lhomme
authors.forename: C
authors.initials: C
authors.lastname: Haie-Meder
authors.forename: D
authors.initials: D
authors.lastname: Castaigne
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000473:pathology; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*
chemical_list: D000970:Antineoplastic Agents